PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-9.16
Negative P/E while Drug Manufacturers - Specialty & Generic median is -0.89. Seth Klarman would scrutinize path to profitability versus peers.
11.56
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.79. Jim Chanos would check for potential multiple compression risks.
0.61
P/B less than half the Drug Manufacturers - Specialty & Generic median of 1.23. Joel Greenblatt would investigate if assets are truly impaired. Check ROE versus peers.
-102.33
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -3.83. Seth Klarman would investigate cash flow improvement potential.
-129.15
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is -2.09. Seth Klarman would investigate operational improvement potential.
0.61
Fair value ratio less than half the Drug Manufacturers - Specialty & Generic median of 1.27. Joel Greenblatt would investigate if this discount is justified.
-2.73%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is -0.58%. Seth Klarman would investigate path to profitability.
-0.98%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -0.54%. Seth Klarman would investigate cash flow improvement potential.